Compass Pathways Nears FDA Filing for Psilocybin Depression Treatment
Event summary
- Compass Pathways reported Q2 2026 revenue and progress toward FDA filing for COMP360, its psilocybin treatment for treatment-resistant depression (TRD).
- The company expects to complete its New Drug Application (NDA) submission in Q4 2026.
- COMP360 demonstrated rapid onset, sustained durability, and infrequent dosing in Phase 3 trials involving over 1,000 participants.
- Compass Pathways reported a net loss of $253.8 million for Q2 2026, driven by non-cash fair value adjustments related to warrants.
The big picture
Compass Pathways is positioning itself at the forefront of a mental health treatment revolution with its psilocybin-based therapy. The company's progress toward FDA approval reflects broader industry trends toward psychedelic-assisted therapies for conditions like TRD and PTSD. With over 4 million individuals in the US living with TRD, COMP360 has the potential to establish a new standard of care if approved.
What we're watching
- Regulatory Approval
- The pace at which the FDA reviews and approves COMP360, potentially accelerated by a National Priority Voucher.
- Commercial Launch
- Whether Compass Pathways can successfully launch COMP360 in the first half of 2027, subject to FDA approval and DEA rescheduling.
- Market Adoption
- How quickly healthcare providers and patients adopt COMP360, given its differentiated profile and potential blockbuster opportunity.
Related topics